Myriad Genetics (MYGN) EBITDA Margin (2009 - 2026)

Myriad Genetics has disclosed EBITDA Margin across 18 years of filings, most recently posting 15.32% for Q1 2026.

• In Q1 2026, EBITDA Margin fell 52.0% year-over-year to 15.32%; the TTM figure through Mar 2026 stood at 46.91% (down 3194.0% YoY), while the FY2025 annual figure was 46.96%, down 3222.0% from the prior year.
• EBITDA Margin eased to 15.32% in Q1 2026, from 2.72% in the prior quarter.
• Over the last five years, EBITDA Margin for MYGN reached as high as 2.72% in Q4 2025 and fell as low as 154.48% in Q2 2025.
• The 5-year median for EBITDA Margin is 15.97% (2023), against an average of 28.19%.
• Annual changes were most pronounced in 2024 — EBITDA Margin surged 4470 bps — and 2025, when it slumped 13722 bps.
• A 5-year view of EBITDA Margin shows it stood at 29.36% in 2022, then jumped by 46 bps to 15.97% in 2023, then decreased by 16 bps to 18.52% in 2024, then jumped by 85 bps to 2.72% in 2025, then sank by 464 bps to 15.32% in 2026.
• According to Business Quant data, EBITDA Margin over the past three periods registered 15.32%, 2.72%, and 11.33% for Q1 2026, Q4 2025, and Q3 2025 respectively.